We described a careful validation of antibody probes for this pair and found CD200 and CD200R to be overexpressed in 29.7% and 25% of NSCLC patients, respectively; stromal expression of CD200R was significantly increased in patients with squamous histology. The gene discussed is CD200; the disease is non-small cell lung carcinoma.